Breaking News

Lilly Licenses QurAlis’ ALS Precision Therapy for $45M Upfront

QRL-204 designed to restore UNC13A function in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

QurAlis Corp. has entered into an exclusive license agreement with Eli Lilly and Co. in which QurAlis is granting Lilly global rights to develop and commercialize QRL-204, a potentially best-in-class splice-switching antisense oligonucleotide (ASO) designed to restore UNC13A function in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases.   Under the agreement, QurAlis granted Lilly an exclusive, worldwide license to develop and commercializ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters